Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viking Thera
(NQ:
VKTX
)
50.35
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Thera
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
November 01, 2024
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.
Via
Investor's Business Daily
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
October 31, 2024
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors
Via
MarketBeat
This High-Flying Stock Just Became a Better Buy
October 31, 2024
It might not be too late to get in on the party.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Viking Therapeutics
October 29, 2024
Via
Benzinga
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
October 28, 2024
Via
Benzinga
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
October 27, 2024
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
Via
The Motley Fool
3 Health Care Stocks Moving In Thursday's Intraday Session
October 24, 2024
Via
Benzinga
An Overview of Viking Therapeutics's Earnings
October 22, 2024
Via
Benzinga
Market Whales and Their Recent Bets on VKTX Options
October 22, 2024
Via
Benzinga
S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump
October 25, 2024
US benchmark equity averages rose on Friday as the market ended a three-day losing streak.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
October 25, 2024
The major indexes were mixed for the week.
Via
Investor's Business Daily
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
October 24, 2024
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
October 10, 2024
Via
Benzinga
Viking Therapeutics Unusual Options Activity
October 08, 2024
Via
Benzinga
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
October 24, 2024
Via
Benzinga
How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet
October 24, 2024
Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss.
Via
Investor's Business Daily
Exposures
Product Safety
3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia)
October 24, 2024
Regardless of who wins the presidency, investors are better off focusing on top growth stocks.
Via
The Motley Fool
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Via
Benzinga
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
October 22, 2024
Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD.
Via
Benzinga
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
October 17, 2024
Viking recently announced the results of an early-stage clinical trial for VK0214.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
October 16, 2024
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
Via
Investor's Business Daily
Where Will Viking Therapeutics Be in 5 Years?
October 14, 2024
We could be witnessing the birth of a major player in the biotech industry.
Via
The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
October 13, 2024
It's hard to go wrong with either company, but one is more appealing.
Via
The Motley Fool
The Ultimate Biotech Stock to Buy With $100 Right Now
October 12, 2024
This company is operating in one of today's hottest markets.
Via
The Motley Fool
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Via
Benzinga
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
October 09, 2024
Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued...
Via
Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
October 07, 2024
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Via
The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
Why Viking Therapeutics Stock Topped the Market Today
September 30, 2024
An analyst waxed bullish on the company's leading pipeline program.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.